Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal

Abstract

Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians. Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran. Idarucizumab was approved in 2015 by the US Food and Drugs Administration and European Medicines Agency for reversal of anticoagulation activity in dabigatrantreated patients. This review briefly summarizes the experimental evidence about effectiveness and safety of idarucizumab. Furthermore, we review the current recommendations and experts’ point of view about the use of antidotes/reversal agents in patients reporting a major bleeding event.

New safety standards for anticoagulant therapy in the treatment of atrial fibrillation

“…Связь идаруцизумаба с дабигатраном более чем в 300 раз выше, чем связь дабигатрана с тромбином (рис. 1) [22]. Идаруцизумаб вводится внутривеннодве дозы по 2,5 г болюсно в двух флаконах по 50 мл или в течение 15 мин капельно.…”